# Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

> **NCT02575508** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Colon Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Rectal Adenocarcinoma
- Stage III Pancreatic Cancer
- Stage IIIA Colon Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Colon Cancer
- Stage IIIB Rectal Cancer
- Stage IIIC Colon Cancer
- Stage IIIC Rectal Cancer
- Stage IV Pancreatic Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Oxaliplatin
- **DRUG:** pan FGFR Kinase Inhibitor BGJ398
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02575508
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2020-05
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** drug supply issues
- **Last updated:** 2016-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575508, "Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02575508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*